Sam Chun Dang Pharm. Co., Ltd announced that it expects to receive KRW 30 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm, and another investors
February 23, 2021
Share
Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:A000250) announced a private placement of series 3 non-guaranteed private convertible bond for gross proceeds of KRW 30,000,000,000 on February 24, 2021. The transaction will include participation from new investors Korea Investment & Securities Co., Ltd., Investment Arm for KRW 5,000,000,000, S.W.S New Technology Association for KRW 22,000,000,000, NH Investment & Securities Co., Ltd., Investment Arm for KRW 2,000,000,000, and KB Securities Co., Ltd., Investment Arm for KRW 1,000,000,000. The bonds will be issued at par. The bonds will not carry any coupon and yield to maturity. The bond would mature on February 26, 2024. The convertible bonds will be 100% convertible into 482,599 common shares at a fixed conversion price of KRW 62,163 per share from February 26, 2022 to January 26, 2024. The securities will have hold period of one year, post the closing. The subscription date and payment date is February 26, 2021. The transaction has been approved by the board of directors of the company.
SAM CHUN DANG PHARM. CO., LTD is a Korea-based company mainly engaged in the manufacture of prescription medicines. The Companyâs products portfolio consists of antibiotics used for treatment of sepsis, respiratory diseases and others; circulatory disease medicines including cardiovascular and endocrine medicaments used for treatment of diabetes, hypertension, angina and others under the brand names of Glilazide and Atenolol; digestive medicines used for treatment of duodenal ulcer, gastritis and others; ophthalmological agents used for treatment of conjunctivitis, keratitis and other eye inflammation under the brand names of Ofus and Toracin, and anti-inflammatories used to release postoperative pains under the brand name Barotase and others.
Sam Chun Dang Pharm. Co., Ltd announced that it expects to receive KRW 30 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm, and another investors